Evidence map›Paper›PMID 41054665›Full record

ArticleCureus2025

Pathologic Complete Response to Neoadjuvant Radiation Therapy in a Primary Pancreaticoduodenal High-Grade Sarcoma.

Jenna R Rocchetti, Jeffrey M Farma, Alessandro Bombonati, Mehri Mollaee, Jeremy Price

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jenna R RocchettiRadiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.
Jeffrey M FarmaSurgical Oncology, Fox Chase Cancer Center, Philadelphia, USA.
Alessandro BombonatiClinical Pathology, Temple University Hospital, Philadelphia, USA.
Mehri MollaeeClinical Pathology, Temple University Hospital, Philadelphia, USA.
Jeremy PriceRadiation Oncology, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade intra-abdominal sarcomas are a rare soft tissue malignancy with a high propensity to present in a locally advanced fashion. The role of radiation therapy (RT) in the management of intra-abdominal sarcomas is relatively under-reported, in contrast to its use in retroperitoneal or extremity sarcomas. We thereby present a case of a 63-year-old female presenting with abdominal pain, gastrointestinal (GI) bleeding, and weight loss, found to have a large, high-grade intra-abdominal pancreaticoduodenal sarcoma. Given ongoing bleeding, absence of actionable mutations, and surgical risk, she was treated with neoadjuvant RT (50 Gray in 25 fractions) using image-guided volumetric-modulated arc therapy. The patient tolerated treatment well with rapid and significant tumor regression, allowing for subsequent pancreaticoduodenectomy. Pathology revealed a complete pathologic response (ypT0N0M0) with no residual viable tumor. At 2.5 years post-treatment, she remains disease-free. This case highlights the potential role of neoadjuvant RT in achieving local control and facilitating curative resection in patients with high-grade intra-abdominal sarcomas. While evidence is limited, especially for visceral intra-abdominal sites, this report supports further investigation into RT as a component of multimodal therapy in select cases.

Indexed as

high-grade intraabdominal sarcomapancreaticoduodenal sarcomapathologic complete responseradiation therapysoft tissue sarcoma

Identifiers

PMID41054665
PMCPMC12497501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.